RT Journal Article
SR Electronic
T1 HIV service interruptions during the COVID-19 pandemic in China: the role of HIV service challenges and institutional response from healthcare professional’s perspective
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.12.21253463
DO 10.1101/2021.03.12.21253463
A1 Yang, Xueying
A1 Zeng, Chengbo
A1 Tam, Cheuk Chi
A1 Qiao, Shan
A1 Li, Xiaoming
A1 Shen, Zhiyong
A1 Zhou, Yuejiao
YR 2021
UL http://medrxiv.org/content/early/2021/03/15/2021.03.12.21253463.abstract
AB Background The healthcare system in China was largely overwhelmed during the unprecedented pandemic of coronavirus disease (COVID-19). HIV-related services have been unavoidably interrupted and impacted. However, the nature and scope of HIV service interruptions due to COVID-19 has rarely been characterized in China and how HIV service challenges affect the service interruptions are also unclear. The current study aimed at characterize HIV service interruption levels and analyzed its associated factors related to service challenges and institutional response from HIV healthcare providers’ viewpoint.Methods A cross-sectional online survey was conducted among 1,029 HIV healthcare providers in Guangxi, China, from April to May 2020. Latent class analysis (LCA) was first used to identify HIV service interruption levels. Then hierarchical multinomial logistic regression was conducted to analyze the relationships of HIV care service challenges and institutional response with HIV service interruption levels. Simple slope analysis was employed to examine interaction effects between HIV service challenges and institutional response to COVID-19.Results Four classes of HIV service interruption were identified using LCA, with 22.0% complete interruption (class 1), 15.4% moderate interruption (class 2), 21.9% minor interruption (class 3) and 40.7% almost no interruption (class 4). Using class 4 as a reference group, HIV care service challenges were positively associated with the probabilities of service interruptions (Class 1: AOR=1.23, 95%CI: 1.19∼1.26; Class 2: AOR= 1.10, 95%CI: 1.08∼1.13; Class 3: AOR= 1.10, 95%CI: 1.08∼1.12). Institutional response to HIV healthcare delivery was negatively associated with the probabilities of being classified into Class 1 (“Complete interruption”) (AOR=0.97, 95%CI: 0.93∼1.00) and Class 3 (“minor interruption [Outreach service]”) (AOR=0.96, 95%CI: 0.93∼0.99) as compared to Class 4 (“almost no interruption”). Institutional response to HIV healthcare delivery moderated the association of HIV service challenges with complete interruption, but not with the moderate or minor interruption when comparing with no interruption group.Conclusions A substantial HIV service interruptions occurs due to the COVID-19 pandemic, particularly services that require face-to-face interactions, such as VCT counselling, follow up and outreach services. HIV service challenges largely hinder the HIV service delivery. Institutional response to HIV healthcare delivery could marginally buffer the negative effect of service challenges on complete HIV service interruptions. To maintain continuity of core HIV services in face of a pandemic, build a resilient health care system with adequate preparedness is necessary.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the National Institute of Mental Health of National Institutes of Health under Award Number NIH/NIMHR01MH0112376 and National Science Foundation of China (NSFC) [grant number 81761128004].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research protocol was approved by the Institutional Review Boards at both the University of South Carolina in the United States and the Guangxi CDC in China.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request from the corresponding author.